[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"continuous-glucose-measurement\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:continuous-glucose-measurement":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100517174","predictive-value-of-glycemic-parameters-measured-with-the-fsl-pro-iq-during-acs-100517174",false,"NCT06014112","Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS","Predictive Value of Glycemic Parameters Measured With the Freestyle Libre Pro iQ During Acute Coronary Syndrome","FREESCA","Inclusion Criteria:\n\n* Patients with ACS managed in a cardiac intensive care unit (ICU). The diagnosis of ACS will be made in the presence of chest pain with ST-segment elevation on the ECG for STEMI or ST-segment change and\u002For a positive troponin cycle (values in accordance with the center's protocol) for NSTEMI.\n\nExclusion Criteria:\n\n* Subjects in cardiogenic or septic shock\n* Subjects with ACS initially managed in a non-investigating center\n* Failure to obtain free, informed, written consent signed by the participant and investigator upon admission to the ICU\n* Person participating in another research study with an ongoing exclusion period\n* Subjects participating in a study that may have an impact on post ACS prognosis\n* Person deprived of his or her rights, person under guardianship or curatorship\n* Person deprived of liberty (by judicial or administrative decision)\n* Persons whose physical and\u002For psychological health is severely impaired, which, in the opinion of the investigator, may affect the participant's compliance to the study\n* Pregnant or breastfeeding women\n* Person who is not affiliated to a social security system or who is a beneficiary of such a system.","ALL","18 Years","85 Years",{"count":21,"type":22},850,"ESTIMATED","INTERVENTIONAL",[25],"NA","Disorders of glycemic regulation are common in patients hospitalized for acute coronary syndrome (ACS). Abnormal glycaemia is observed in 50% of cases, in 30-40% diabetes, and in 25-35% fasting hyperglycaemia or glucose intolerance.\n\nHyperglycemia is a major prognostic factor in ACS, with admission hyperglycemia having independent prognostic value for both short- and long-term major cardiovascular events (MACE), regardless of the presence of diabetes.\n\nMetabolically, several situations can be distinguished:\n\n* Hyperglycaemia occurs in known non-diabetic ACS subjects. It can be indicative of (i) Type 2 Diabetes or (ii) stress hyperglycaemia (diagnostic threshold for blood sugar varies according to learned societies, with HbA1c \\\u003C 6.5%).\n* Hyperglycaemia occurs in known diabetic ACS subjects Most studies use admission blood sugar as a predictor. However, it has recently been shown that glycemic variability indexes would be better predictors of MACE. Using continuous glucose measurement for 48 h, it has been shown that significant glycemic variability is a more powerful predictor of MACE at 1 year than admission glycemia The measurement of glycemic variability is mainly possible thanks to the development of CGM (continuous glucose measurement).\n\nTo our knowledge, no study has been interested in evaluating the predictive value of the various glycemic parameters measured by CGM.\n\nPublished studies have used continuous glucose measurements for very short periods (24 or 72 hours maximum), which limits these measurements.\n\nThe freestyle libre Pro iQ (FSLPro iQ) is a professional sensor for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.\n\nOur hypothesis is that glycaemic parameters, alone or in combination with each other or with other patient risk factors, measured with the Freestyle libre Pro iQ have a significant prognostic value in terms of cardiovascular clinical events at 12 months in a population of patients with ACS managed as standard and followed up.",[28,29,30,31],"Acute Coronary Syndrome","Continuous Glucose Measurement","Glycemic Variability","Cardiovascular Event",[33,34,35,36],"acute coronary syndrome","continuous glucose measurement","glycemic variability","cardiovascular event","RECRUITING","2026-06-11",{"date":40,"type":41},"2026-06-12","ACTUAL",{"date":43,"type":41},"2023-11-06",{"date":45,"type":22},"2028-05-06",{"name":47,"class":48},"University Hospital, Montpellier","OTHER",9,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100568703","individualized-automatic-coaching-message-for-glycemic-management-and-depressive-symptom-100568703","NCT06684678","Individualized Automatic Coaching Message for Glycemic Management and Depressive Symptom","Efficacy of Individualized Automatic Coaching Message Based on the Metrics of Continuous Glucose Monitoring and Depressive Symptom: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with type 1 diabetes, age 18-75 years old\n* Patients who have used continuous glucose monitoring at least three months and have enrolled in Type 1 Diabetes Home Care Project and Educational Consultation program.\n* Patients with at least 70% of 14 days of continuous glucose monitor data within the past month\n* Glycated hemoglobin 7% or higher, or Glycated hemoglobin 6% or higher but less than 7% and failing to meet 1 of the continuous glucose monitor blood glucose target values: time in range (70-180 mg\u002FL) 70% or less, or time below range (\\\u003C70 mg\u002FL) 4% or more, or time above range (\\>180 mg\u002FL) 25% or more, or glucose management indicator (GMI) 7% or more, or coefficient of variation (CV%) 36% or more.\n* Currently receiving treatment with multiple insulin injection therapy\n* Patients who have access to KakaoTalk via smartphone and are able to communicate with it\n* Voluntarily agreed to participate in this clinical study.\n\nExclusion Criteria:\n\n* Steroid and immunosuppressant users. But it can be included if patients continuously maintain same drug dose at least three months.\n* Breastfeeding or pregnant patients\n* Patients who do not voluntarily consent to the study\n* Anyone deemed unsuitable by the investigator to participate in the study","75 Years",{"count":59,"type":22},140,[25],"This is a single-center, randomized, prospective, confirmatory study of efficacy of individualized automatic coaching message for glycemic management and depressive symptom in patients with type 1 diabetes. The study will enroll patients with type 1 diabetes who are applying continuous glucose monitoring (CGM) and receiving twice-monthly non-face-to-face management by a dedicated education nurse through the Type 1 Diabetes Home Care Project and Educational Consultation program. For 12 weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires, instead of non-face-to-face diabetes management. The control group will continue their current treatment and non-face-to-face diabetes management. The aim of this study is to evaluate whether the efficacy of automated, personalized coaching messages for glycemic management and depressive symptoms is non-inferior to the current non-face-to-face management approach in people with type 1 diabetes.",[63,29],"Diabetes Mellitus, Type 1",[65,66,67],"type 1 diabetes","continuous glucose monitoring","depressive symptom","NOT_YET_RECRUITING","2024-11-11",{"date":71,"type":41},"2024-11-13",{"date":71,"type":22},{"date":74,"type":22},"2025-04-30",{"name":76,"class":48},"Samsung Medical Center",1]